O	0	4	Late
B-intervention	5	14	tamoxifen
O	15	17	in
O	18	26	patients
O	27	37	previously
O	38	46	operated
O	47	50	for
O	51	57	breast
O	58	64	cancer
O	65	72	without
O	73	86	postoperative
O	87	96	tamoxifen
O	96	97	:
O	98	99	5
O	99	100	-
O	100	104	year
O	105	112	results
O	113	115	of
O	116	117	a
O	118	124	single
O	125	136	institution
O	137	147	randomised
O	148	153	study
O	153	154	.

O	155	156	A
O	157	167	population
O	168	170	of
O	171	177	breast
O	178	184	cancer
O	185	193	patients
O	194	200	exists
O	201	204	who
O	204	205	,
O	206	209	for
O	210	217	various
O	218	225	reasons
O	225	226	,
O	227	232	never
O	233	241	received
O	242	250	adjuvant
O	251	255	post
O	255	256	-
O	256	265	operative
O	266	275	tamoxifen
O	276	277	(
O	277	280	TAM
O	280	281	)
O	281	282	.

O	283	287	This
O	288	293	study
O	294	297	was
O	298	303	aimed
O	304	306	to
O	307	315	evaluate
O	316	319	the
O	320	324	role
O	325	327	of
O	328	332	late
O	333	336	TAM
O	337	339	in
O	340	345	these
O	346	354	patients
O	354	355	.

O	356	360	From
O	361	365	1997
O	366	368	to
O	369	373	2003
O	373	374	,
O	375	383	patients
O	384	388	aged
B-age	389	391	35
I-age	392	394	to
I-age	395	397	75
I-age	398	403	years
O	403	404	,
B-eligibility	405	413	operated
I-eligibility	414	418	more
I-eligibility	419	423	than
I-eligibility	424	425	2
I-eligibility	426	431	years
I-eligibility	432	442	previously
I-eligibility	443	446	for
I-eligibility	447	458	monolateral
I-eligibility	459	465	breast
I-eligibility	466	472	cancer
I-eligibility	473	480	without
I-eligibility	481	489	adjuvant
I-eligibility	490	493	TAM
I-eligibility	493	494	,
I-eligibility	495	499	with
I-eligibility	500	502	no
I-eligibility	503	508	signs
I-eligibility	509	511	of
I-eligibility	512	522	metastases
I-eligibility	523	526	and
I-eligibility	527	529	no
I-eligibility	530	546	contraindication
I-eligibility	547	549	to
I-eligibility	550	553	TAM
O	554	558	were
O	559	569	randomized
O	570	572	to
O	573	576	TAM
O	577	579	20
O	580	582	mg
O	582	583	/
O	583	586	day
O	587	593	orally
O	594	597	for
O	598	599	2
O	600	605	years
O	606	608	or
B-control	609	615	follow
I-control	615	616	-
I-control	616	618	up
I-control	619	624	alone
O	624	625	.

O	626	632	Events
O	633	637	were
O	638	649	categorized
O	650	652	as
O	653	665	locoregional
O	666	673	relapse
O	673	674	,
O	675	682	distant
O	683	693	metastases
O	693	694	,
O	695	707	metachronous
O	708	714	breast
O	715	721	cancer
O	721	722	,
O	723	730	tumours
O	731	736	other
O	737	741	than
O	742	748	breast
O	749	755	cancer
O	756	759	and
O	760	765	death
O	766	770	from
O	771	774	any
O	775	781	causes
O	781	782	,
O	783	792	whichever
O	793	801	occurred
O	802	807	first
O	807	808	.

O	809	812	The
O	813	819	sample
O	820	824	size
O	825	826	(
O	826	829	197
O	830	838	patients
O	839	842	per
O	843	846	arm
O	846	847	,
O	848	852	plus
O	853	855	10
O	855	856	%
O	857	866	allowance
O	866	867	)
O	868	871	was
O	872	877	based
O	878	880	on
O	881	884	the
O	885	895	assumption
O	896	898	of
O	899	900	a
O	901	903	30
O	903	904	%
O	905	913	decrease
O	914	916	in
O	917	920	the
O	921	927	number
O	928	930	of
O	931	937	events
O	938	947	occurring
O	948	950	at
O	951	952	a
O	953	957	rate
O	958	960	of
O	961	962	5
O	962	963	%
O	964	972	annually
O	973	975	in
O	976	979	the
O	980	982	10
O	983	988	years
O	989	998	following
O	999	1012	randomization
O	1012	1013	.

B-total-participants	1014	1018	Four
I-total-participants	1019	1026	hundred
I-total-participants	1027	1030	and
I-total-participants	1031	1037	thirty
I-total-participants	1037	1038	-
I-total-participants	1038	1043	three
O	1044	1052	patients
O	1053	1057	were
O	1058	1068	randomized
O	1069	1071	in
O	1072	1075	the
O	1076	1081	study
O	1082	1083	(
O	1083	1086	TAM
B-intervention-participants	1087	1090	217
O	1090	1091	,
B-control	1092	1098	follow
I-control	1098	1099	-
I-control	1099	1101	up
B-control-participants	1102	1105	216
O	1105	1106	)
O	1106	1107	.

O	1108	1116	Patients
O	1117	1132	characteristics
O	1133	1134	(
O	1134	1137	TAM
O	1137	1138	/
O	1138	1144	follow
O	1144	1145	-
O	1145	1147	up
O	1147	1148	)
O	1149	1157	included
O	1157	1158	:
O	1159	1165	median
O	1166	1169	age
O	1170	1172	55
O	1172	1173	/
O	1173	1175	55
O	1176	1181	years
O	1181	1182	,
O	1183	1189	median
O	1190	1194	time
O	1195	1199	from
O	1200	1207	surgery
O	1208	1210	25
O	1210	1211	/
O	1211	1213	25
O	1214	1220	months
O	1221	1222	(
O	1222	1227	range
O	1227	1228	,
O	1229	1231	25
O	1231	1232	-
O	1232	1235	288
O	1235	1236	/
O	1236	1238	25
O	1238	1239	-
O	1239	1242	294
O	1242	1243	)
O	1243	1244	,
O	1245	1247	in
O	1248	1252	situ
O	1253	1262	carcinoma
O	1263	1265	18
O	1265	1266	/
O	1266	1268	24
O	1268	1269	,
O	1270	1279	oestrogen
O	1280	1288	receptor
O	1289	1290	(
O	1290	1292	ER
O	1292	1293	)
O	1294	1302	positive
O	1303	1305	in
O	1306	1308	75
O	1308	1309	/
O	1309	1311	68
O	1311	1312	,
O	1313	1321	negative
O	1322	1324	in
O	1325	1327	70
O	1327	1328	/
O	1328	1330	57
O	1330	1331	,
O	1332	1339	unknown
O	1340	1342	in
O	1343	1345	72
O	1345	1346	/
O	1346	1348	91
O	1349	1357	patients
O	1357	1358	.

O	1359	1367	Previous
O	1368	1376	adjuvant
O	1377	1386	treatment
O	1387	1395	included
O	1396	1408	chemotherapy
O	1409	1411	in
O	1412	1415	131
O	1415	1416	/
O	1416	1419	120
O	1420	1423	and
O	1424	1426	an
O	1427	1431	LHRH
O	1432	1440	analogue
O	1441	1443	in
O	1444	1446	11
O	1446	1447	/
O	1447	1449	13
O	1450	1458	patients
O	1458	1459	.

B-iv-bin-abs	1460	1466	Thirty
I-iv-bin-abs	1466	1467	-
I-iv-bin-abs	1467	1470	six
O	1471	1479	patients
B-outcome	1480	1491	prematurely
I-outcome	1492	1504	discontinued
O	1505	1508	TAM
O	1509	1514	after
O	1515	1516	a
O	1517	1523	median
O	1524	1526	of
O	1527	1528	1
O	1529	1534	month
O	1534	1535	,
O	1536	1542	mostly
O	1543	1550	because
O	1551	1553	of
O	1554	1564	subjective
O	1565	1576	intolerance
O	1576	1577	.

O	1578	1584	Eighty
O	1584	1585	-
O	1585	1590	three
B-outcome	1591	1597	events
O	1598	1599	(
O	1599	1602	TAM
B-iv-bin-abs	1603	1605	39
O	1605	1606	,
O	1607	1613	follow
O	1613	1614	-
O	1614	1616	up
B-cv-bin-abs	1617	1619	44
O	1619	1620	)
O	1621	1629	occurred
O	1629	1630	:
B-outcome	1631	1643	locoregional
I-outcome	1644	1651	relapse
O	1652	1654	in
B-iv-bin-abs	1655	1657	10
O	1657	1658	/
B-cv-bin-abs	1658	1659	8
O	1659	1660	,
B-outcome	1661	1668	distant
I-outcome	1669	1679	metastases
O	1680	1682	in
B-iv-bin-abs	1683	1685	14
O	1685	1686	/
B-cv-bin-abs	1686	1688	16
O	1688	1689	,
B-outcome	1690	1702	metachronous
I-outcome	1703	1709	breast
I-outcome	1710	1716	cancer
O	1717	1719	in
B-iv-bin-abs	1720	1721	4
O	1721	1722	/
B-cv-bin-abs	1722	1724	10
O	1724	1725	,
B-outcome	1726	1731	other
I-outcome	1732	1739	tumours
O	1740	1742	in
B-iv-bin-abs	1743	1745	11
O	1745	1746	/
B-cv-bin-abs	1746	1748	10
O	1749	1757	patients
O	1757	1758	.

O	1759	1763	Less
B-outcome	1764	1766	ER
I-outcome	1766	1767	-
I-outcome	1767	1775	positive
I-outcome	1776	1785	secondary
I-outcome	1786	1792	breast
I-outcome	1793	1800	cancers
O	1801	1809	occurred
O	1810	1812	in
O	1813	1816	the
O	1817	1820	TAM
O	1821	1828	treated
O	1829	1837	patients
O	1838	1842	than
O	1843	1845	in
O	1846	1852	follow
O	1852	1853	-
O	1853	1855	up
O	1856	1864	patients
O	1865	1866	(
B-iv-bin-abs	1866	1867	1
O	1868	1870	vs
B-cv-bin-abs	1871	1873	10
O	1873	1874	,
O	1875	1876	p
O	1877	1878	=
O	1879	1880	0
O	1880	1881	.
O	1881	1884	005
O	1884	1885	)
O	1885	1886	.

B-outcome	1887	1892	Event
I-outcome	1892	1893	-
I-outcome	1893	1897	free
I-outcome	1898	1906	survival
O	1907	1910	was
O	1911	1918	similar
O	1919	1921	in
O	1922	1926	both
O	1927	1933	groups
O	1934	1936	of
O	1937	1945	patients
O	1945	1946	.

O	1947	1951	This
O	1952	1953	5
O	1953	1954	-
O	1954	1958	year
O	1959	1967	analysis
O	1968	1976	revealed
O	1977	1990	significantly
O	1991	1995	less
O	1996	2008	metachronous
O	2009	2011	ER
O	2011	2012	-
O	2012	2020	positive
O	2021	2027	breast
O	2028	2035	cancers
O	2036	2038	in
O	2039	2042	the
O	2043	2046	TAM
O	2047	2054	treated
O	2055	2063	patients
O	2063	2064	.

O	2065	2067	No
O	2068	2073	other
O	2074	2087	statistically
O	2088	2099	significant
O	2100	2111	differences
O	2112	2116	have
O	2117	2124	emerged
O	2125	2129	thus
O	2130	2133	far
O	2133	2134	.
